A Study to Evaluate DMR-001 in Participants With CALR-mutant Myeloproliferative Neoplasms

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
This is a multi-center, open-label, Phase 1/1b study designed to evaluate the safety, pharmacokinetics, immunogenicity, and preliminary efficacy of DMR-001 monotherapy in adult participants with CALR-mutated essential thrombocythemia (ET) and myelofibrosis (MF), and of DMR-001 in combination with ruxolitinib in participants with CALR-mutant MF.
Epistemonikos ID: 712376dcf7d4e95b416b0c86898e588553275de3
First added on: Oct 01, 2026